AustraliaHealth

Xenitra (ASX:XEN) announced the 100% acquisition of Hong Kong Fukang Trading.

PYC Therapeutics (ASX:PYC) advances its PYC-001 drug candidate to multiple-dose testing for blinding eye disease ADOA.

FDA granted Immutep (ASX:IMM) Orphan Drug Designation for eftilagimod alfa in soft tissue sarcoma.

Orthocell (ASX:OCC) secured approval to supply its Remplir nerve repair device to 221 DoD and Veterans Affairs hospitals.

Genetic Signatures (ASX:GSS) has signed a multi-year supply agreement with Denmark's Hvidovre Hospital.

Mesoblast (ASX:MSB) has acquired an exclusive worldwide licence for a chimeric antigen receptor technology platform.

AVITA Medical (ASX:AVH) unveiled interim data from its Cohealyx-I multi-centre study.

Ryman Healthcare (ASX:RYM) reported a 10% lift in Q4 sales, meeting FY26 guidance despite village closures.

Telix Pharmaceuticals (ASX:TLX) announced the launch of a US$550 million offering of senior unsecured convertible notes due 2031.

PainChek (ASX:PCK) announced a master services agreement with Sabra Health Care REIT (NASDAQ:SBRA).

Noxopharm (ASX:NOX) has announced the resignation of its CEO and Managing Director, Dr Gisela Mautner.

Entropy Neurodynamics (ASX:ENP) announced a pivotal breakthrough in its TRP-8803 clinical programme.